ArticleJournal of molecular histology2025
miR-429 suppresses progression and metastasis of salivary adenoid cystic carcinoma by targeting ZEB1.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- MicroRNAs in Salivary Gland Cancers Associated with Poor Prognosis: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- MEOX1 Inhibits Growth and Metastasis of Salivary Adenoid Cystic Carcinoma.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
miR-429 is a tumor suppressor that has been observed in various cancers. The exact mechanism by which miR-429 affects salivary adenoid cystic carcinoma(SACC) is not fully understood. Initially, the expression of miR-429 and zinc finger E-box-binding homeobox 1 (ZEB1) in tumor tissues and matched adjacent non-tumor tissues of SACC patients were inspected by quantitative real-time polymerase chain reaction. Next, CCK-8, wound healing, transwell, and dorsal root ganglion (DRG) co-culture models were used to explore the effects of miR-429 on SACC cell proliferation, migration, invasion, and perineural invasion (PNI). Finally, the downstream target genes of miR-429 were screened and validated through bioinformatics analysis and dual-luciferase reporter analysis, and the regulatory role of miR-429 on epithelial-mesenchymal transition (EMT) in SACC cells was explored. miR-429 was poorly expressed while ZEB1 was substantially expressed in SACC tumor tissues. Elevated levels of miR-429 led to a significant suppression of SACC cell of proliferation, migration, invasion, and PNI. ZEB1 was screened and validated as a downstream target gene of miR-429. High concentrations of miR-429 also markedly lowered the expression of ZEB1 in SACC cells, thereby inhibiting EMT. These results suggest that miR-429 is lowly expressed in SACC, may suppress progression and metastasis of SACC cells, and is associated with ZEB1 and the EMT pathway.
Indexed as
Identifiers
40632321What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.